Long-term observation of atopic dermatitis and related allergic conditions
Prospective Longitudinal Observational Research Study to Investigate the Remission of Atopic Dermatitis and Associated Allergic Diseases
This project will collect medical and lab data over time to see which genetic, immune, environmental, and microbial factors relate to the course or remission of atopic dermatitis and other atopic diseases in people of all ages.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 1 Year to 85 Years |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Trial ID | NCT04240522 on ClinicalTrials.gov |
What this trial studies
This is a prospective, longitudinal observational cohort that will enroll people with atopic dermatitis and other atopic diseases, plus healthy controls, across ages 0–85. Participants will remain on their medically indicated therapies while clinicians collect standardized clinical data, biosamples, and laboratory measurements over time. The study aims to link endogenous factors (genetic, immunological, molecular) and exogenous factors (environmental, socioeconomic, microbial) to disease course, remission, and the development of related atopic conditions. Collected data will be used to define patient subgroups (endotypes) and search for biomarkers that predict individual clinical trajectories.
Who should consider this trial
Good fit: Ideal candidates are people aged 0–85 with a diagnosis of atopic dermatitis or another atopic disease, and healthy volunteers without allergic disease, who can provide informed consent (or have a guardian provide consent).
Not a fit: People seeking immediate experimental therapies or direct clinical benefit from the protocol are unlikely to gain treatment benefit since this is an observational data-collection project, and those unable to attend follow-up visits or provide samples will not benefit from the study's aims.
Why it matters
Potential benefit: If successful, the findings could enable earlier prediction of flares or remission and support more personalized prevention and treatment strategies for atopic diseases.
How similar studies have performed: Previous longitudinal cohorts have identified some genetic and immune markers linked to atopic march and endotypes, but results have been only partially reproducible and larger, multi-factor studies are still needed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 0 - 85 years * Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy) * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated The inclusion criteria for healthy controls in this study are as follows: * Age 0 - 85 years * No diagnosis or history of allergic disease * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated Written consent will be obtained after detailed information of the study was given to the participant. Exclusion Criteria \- Unable to give consent or refusal to participate in the study
Where this trial is running
Zurich, Canton of Zurich
- Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich — Zurich, Canton of Zurich, Switzerland (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.